🧬 Is your metabolism quietly signaling the earliest signs of future disease?

🔗 Metabolic phenotypes: Molecular bridges between health homeostasis and disease imbalance. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.057

📚 CSBJ: https://www.csbj.org/

#MetabolicPhenotyping #Metabolomics #PrecisionMedicine #MultiOmics #BiomarkerDiscovery #TranslationalMedicine #DiseasePrevention #AIinHealthcare

Nghiên cứu mới giới thiệu phương pháp "lựa chọn cảm biến động" dựa trên lý thuyết quan sát để khám phá dấu ấn sinh học (biomarker). Phương pháp này giúp xác định và diễn giải các tín hiệu sinh học một cách hiệu quả từ lượng lớn dữ liệu, tối ưu hóa việc chọn biomarker theo thời gian. Ứng dụng rộng rãi trong y tế, nông nghiệp, sản xuất sinh học và hệ thần kinh.
#BiomarkerDiscovery #DynamicSensorSelection #ObservabilityTheory #SinhHoc #NghienCuuKhoaHoc #YTe

https://www.reddit.com/r/singularity/com

Esoteric Testing: Going Beyond Standard Testing Approaches

Esoteric Testing involves deliberately designing unconventional test cases aimed at finding hard-to-discover flaws. Rather than following typical usage patterns or common scenarios, esoteric tests push the system to its logical extremes and boundaries to expose weaknesses.

Esoteric Testing-https://themediumblog.com/read-blog/158536

#CoherentMarketInsights #ChronicDiseaseManagement #GenomicTesting #BiomarkerDiscovery #PointofCareTesting

Esoteric Testing: Going Beyond the Surface to Evaluate Deeper Abilities

In today's constantly evolving world, esoteric testing fills gaps in traditional evaluation methods by accounting for less tangible attributes tied to success.

Proteomics Today Where Genomics Was in the 80s: Margaret Donovan and Asim Siddiqui of Seer on Landmark Study

https://mendelspod.com/podcasts/proteomics-today-where-genomics-was-80s-margaret-donovan-and-asim-siddiqui-seer-landmark/

@seer_bio @mkrdonovan #proteomics #biomarkerdiscovery #proteoform

Proteomics Today Where Genomics Was in the 80s: Margaret Donovan and Asim Siddiqui of Seer on Landmark Study

It’s a thrilling time to be in proteomics. Today we discuss a recent paper in PLOS One demonstrating how new technology has revealed a novel biomarker for non-small cell lung cancer previously undetected by other methods. The paper could be a model for new proteomics research going forward. Our guests are Margaret Donovan, Product Marketing Manager, and Asim Siddiqui, Senior VP of Research, both at proteomics company, Seer. “Historically the way in which we’ve been able to analyze the proteome has essentially meant you’re making trade-offs.

Mendelspod